Answers are grounded in this paper and cite their sources.
Real-world study shows upadacitinib achieves remission and adherence in rheumatoid arthritis, suggesting higher effectiveness than other JAK inhibitors.
This real-world study of patients with RA showed that greater proportions of patients who received upadacitinib attained physician-reported DAS28 remission, absence of pain, and complete adherence to medication compared with patients receiving other JAKis.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: